WebOncology; Opportunity-driven; Technologies ... Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. … WebApr 13, 2024 · GSK employees, working on the production of medicine, Brazil Company photo: GSK. GlaxoSmithKline has agreed to buy Sierra Oncology, a US rare cancer therapy company, for $1.9bn (£1.5bn) in cash ...
GSK Glaxo to Buy Biotech Company Sierra Oncology for $1.9 …
WebMay 15, 2012 · Sierra Oncology acquired by GlaxoSmithKline . Sierra Oncology . GlaxoSmithKline . Apr 13, 2024 . 3. Europharm Holding SA acquired by GlaxoSmithKline . ... save to custom lists or to Salesforce, and get notified when new companies, people, or deals meet your search criteria. START FREE TRIAL WebApr 13, 2024 · Cambridge, UK, 13 April 2024 – Sareum Holdings plc (AIM: SAR), the specialist drug development company, notes that Sierra Oncology, Inc (“Sierra”), the licence holder for SRA737 (a novel Chk1 inhibitor), has agreed to be acquired by GlaxoSmithKline plc (“GSK”) for US$1.9 billion in cash. The transaction is expected to close in the ... h and r block pine ridge
GSK completes acquisition of Sierra Oncology GSK US
WebApr 11, 2024 · 4 analysts have issued 1-year target prices for Sierra Oncology's shares. Their SRRA share price forecasts range from $55.00 to $55.00. On average, they expect the company's share price to reach $55.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price. View analysts price targets for SRRA or view top-rated ... WebApr 19, 2024 · GlaxoSmithKline has announced the agreed $1.9bn acquisition of biopharmaceutical company Sierra Oncology, which specialises in treatments for rare forms of cancer. This news comes in the wake of Sierra Oncology’s positive top line results from the MOMENTUM phase III trial earlier this year. The study trialled Sierra’s momelotinib … WebSierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two … h and r block pinellas park